Identifying biomarkers to predict outcomes in progressive fibrosing lung disease
Prognostic Biomarker Development in Progressive Fibrosing Interstitial Lung Disease
This study is looking to find new ways to predict how progressive fibrosing interstitial lung disease (PF-ILD) will get worse, using advanced technology to analyze patient data, so that doctors can better tailor treatments for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11002680 on NIH RePORTER |
What this research studies
This research focuses on progressive fibrosing interstitial lung disease (PF-ILD), a serious condition that leads to significant lung function decline. The team aims to develop and validate biomarkers that can predict the progression of PF-ILD using advanced machine learning techniques applied to proteomic data. By identifying these biomarkers, the research seeks to improve treatment strategies and outcomes for patients suffering from various forms of interstitial lung disease. The study will involve analyzing data from patients to ensure the findings are applicable in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with progressive fibrosing interstitial lung disease, particularly those with non-idiopathic pulmonary fibrosis.
Not a fit: Patients with stable interstitial lung disease or those without a diagnosis of PF-ILD may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better prediction of disease progression and more personalized treatment options for patients with PF-ILD.
How similar studies have performed: Previous research has shown promise in using proteomic signatures for predicting outcomes in lung diseases, indicating potential for success in this novel approach.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Oldham, Justin M — University of Michigan at Ann Arbor
- Study coordinator: Oldham, Justin M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.